Ten things you should know about protein kinases: IUPHAR Review 14

被引:249
作者
Fabbro, Doriano [1 ]
Cowan-Jacob, Sandra W. [2 ]
Moebitz, Henrik [2 ]
机构
[1] PIQUR Therapeut, CH-4057 Basel, Switzerland
[2] Novartis Inst Biomed Res, Basel, Switzerland
基金
英国惠康基金;
关键词
CHRONIC MYELOID-LEUKEMIA; CELL LUNG-CANCER; TYROSINE KINASE; SMALL-MOLECULE; BCR-ABL; ACQUIRED-RESISTANCE; SELECTIVE INHIBITOR; IRREVERSIBLE INHIBITORS; TARGETING KINASES; MAP KINASE;
D O I
10.1111/bph.13096
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Many human malignancies are associated with aberrant regulation of protein or lipid kinases due to mutations, chromosomal rearrangements and/or gene amplification. Protein and lipid kinases represent an important target class for treating human disorders. This review focus on the 10 things you should know about protein kinases and their inhibitors', including a short introduction on the history of protein kinases and their inhibitors and ending with a perspective on kinase drug discovery. Although the 10 things' have been, to a certain extent, chosen arbitrarily, they cover in a comprehensive way the past and present efforts in kinase drug discovery and summarize the status quo of the current kinase inhibitors as well as knowledge about kinase structure and binding modes. Besides describing the potentials of protein kinase inhibitors as drugs, this review also focus on their limitations, particularly on how to circumvent emerging resistance against kinase inhibitors in oncological indications.
引用
收藏
页码:2675 / 2700
页数:26
相关论文
共 296 条
  • [1] Allosteric inhibitors of Bcr-abl-dependent cell proliferation
    Adrián, FJ
    Ding, Q
    Sim, TB
    Velentza, A
    Sloan, C
    Liu, Y
    Zhang, GB
    Hur, W
    Ding, S
    Manley, P
    Mestan, J
    Fabbro, D
    Gray, NS
    [J]. NATURE CHEMICAL BIOLOGY, 2006, 2 (02) : 95 - 102
  • [2] Ibrutinib and Indolent B-Cell Lymphomas
    Akinleye, Akintunde
    Furqan, Muhammad
    Adekunle, Oluwaseyi
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2014, 14 (04) : 253 - 260
  • [3] MEK and the inhibitors: from bench to bedside
    Akinleye, Akintunde
    Furqan, Muhammad
    Mukhi, Nikhil
    Ravella, Pavan
    Liu, Delong
    [J]. JOURNAL OF HEMATOLOGY & ONCOLOGY, 2013, 6
  • [4] Discovery and optimization of triazolopyridazines as potent and selective inhibitors of the c-Met kinase
    Albrecht, Brian K.
    Harmange, Jean-Christophe
    Bauer, David
    Berry, Loren
    Bode, Christiane
    Boezio, Alessandro A.
    Chen, April
    Choquette, Deborah
    Dussault, Isabelle
    Fridrich, Cary
    Hirai, Satoko
    Hoffman, Doug
    Larrow, Jay F.
    Kaplan-Lefko, Paula
    Lin, Jasmine
    Lohman, Julia
    Long, Alexander M.
    Moriguchi, Jodi
    O'Connor, Anne
    Potashman, Michele H.
    Reese, Monica
    Rex, Karen
    Siegmund, Aaron
    Shah, Kavita
    Shimanovich, Roman
    Springer, Stephanie K.
    Teffera, Yohannes
    Yang, Yajing
    Zhang, Yihong
    Bellon, Steven F.
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2008, 51 (10) : 2879 - 2882
  • [5] THE CONCISE GUIDE TO PHARMACOLOGY 2013/14: CATALYTIC RECEPTORS
    Alexander, Stephen P. H.
    Benson, Helen E.
    Faccenda, Elena
    Pawson, Adam J.
    Sharman, Joanna L.
    Spedding, Michael
    Peters, John A.
    Harmar, Anthony J.
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 2013, 170 (08) : 1676 - 1705
  • [6] THE CONCISE GUIDE TO PHARMACOLOGY 2013/14: ENZYMES
    Alexander, Stephen P. H.
    Benson, Helen E.
    Faccenda, Elena
    Pawson, Adam J.
    Sharman, Joanna L.
    Spedding, Michael
    Peters, John A.
    Harmar, Anthony J.
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 2013, 170 (08) : 1797 - 1867
  • [7] Role of c-kit/SCF in cause and treatment of gastrointestinal stromal tumors (GIST)
    Ali, Safdar
    Ali, Sher
    [J]. GENE, 2007, 401 (1-2) : 38 - 45
  • [8] Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity
    Anastassiadis, Theonie
    Deacon, Sean W.
    Devarajan, Karthik
    Ma, Haiching
    Peterson, Jeffrey R.
    [J]. NATURE BIOTECHNOLOGY, 2011, 29 (11) : 1039 - U117
  • [9] Modulation of Activation-Loop Phosphorylation by JAK Inhibitors Is Binding Mode Dependent
    Andraos, Rita
    Qian, Zhiyan
    Bonenfant, Debora
    Rubert, Joelle
    Vangrevelinghe, Eric
    Scheufler, Clemens
    Marque, Fanny
    Regnier, Catherine H.
    De Pover, Alain
    Ryckelynck, Hugues
    Bhagwat, Neha
    Koppikar, Priya
    Goel, Aviva
    Wyder, Lorenza
    Tavares, Gisele
    Baffert, Fabienne
    Pissot-Soldermann, Carole
    Manley, Paul W.
    Gaul, Christoph
    Voshol, Hans
    Levine, Ross L.
    Sellers, William R.
    Hofmann, Francesco
    Radimerski, Thomas
    [J]. CANCER DISCOVERY, 2012, 2 (06) : 512 - 523
  • [10] Phosphoinositide 3-Kinase δ Gene Mutation Predisposes to Respiratory Infection and Airway Damage
    Angulo, Ivan
    Vadas, Oscar
    Garcon, Fabien
    Banham-Hall, Edward
    Plagnol, Vincent
    Leahy, Timothy R.
    Baxendale, Helen
    Coulter, Tanya
    Curtis, James
    Wu, Changxin
    Blake-Palmer, Katherine
    Perisic, Olga
    Smyth, Deborah
    Maes, Mailis
    Fiddler, Christine
    Juss, Jatinder
    Cilliers, Deirdre
    Markelj, Gasper
    Chandra, Anita
    Farmer, George
    Kielkowska, Anna
    Clark, Jonathan
    Kracker, Sven
    Debre, Marianne
    Picard, Capucine
    Pellier, Isabelle
    Jabado, Nada
    Morris, James A.
    Barcenas-Morales, Gabriela
    Fischer, Alain
    Stephens, Len
    Hawkins, Phillip
    Barrett, Jeffrey C.
    Abinun, Mario
    Clatworthy, Menna
    Durandy, Anne
    Doffinger, Rainer
    Chilvers, Edwin R.
    Cant, Andrew J.
    Kumararatne, Dinakantha
    Okkenhaug, Klaus
    Williams, Roger L.
    Condliffe, Alison
    Nejentsev, Sergey
    [J]. SCIENCE, 2013, 342 (6160) : 866 - 871